We create innovative treatments for nervous system damage due to injury or disease.
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury.
View our Corporate Presentation
Subscribe to our mailing list to stay up to date
September 25, 2023
NervGen announced the first subject has been dosed in its landmark Phase 1b/2a proof-of-concept placebo-controlled clinical trial for NVG-291 in individuals with SCI.
August 9, 2023
NervGen reported its financial and operational results for the second quarter ended June 30, 2023.
July 28, 2022
Unlike existing treatments that focus on rehabilitation or reducing the risk of an additional stroke, the experimental drug targets the "stickiness" that can prevent injured brain tissue from functioning as it should